Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.
1. An antisense oligonucleotide against Smad7 consisting of SEQ ID NO: 5:
5′-GTTTGGTCCTGAACATGC-3′, wherein at least one internucleoside linkage is a phosphorothioate linkage.
2. The antisense oligonucleotide of claim 1 wherein all internucleoside linkages are phosphorothioate linkages.
3. The antisense oligonucleotide of claim 1 wherein 2′-deoxyribonucleotides are replaced by corresponding ribonucleotides.
4. A pharmaceutical composition comprising the antisense oligonucleotide of claim 1 and one or more pharmaceutically acceptable adjuvants or excipients.
5. A method of treating Crohn's disease, comprising administering to a patient in need thereof an effective amount of the antisense oligonucleotide of claim 1 .
6. A method of treating ulcerative colitis, comprising administering to a patient in need thereof an effective amount of the antisense oligonucleotide of claim 1 .
7. A method of treating inflammatory bowel disease, comprising administering to a patient in need thereof an effective amount of the antisense oligonucleotide of claim 1 .